ACCESSIBILITY

Oral Cancer Screening (VIZILITE)

Oral cancer is one of the most curable diseases when it's caught early. That's why the ViziLite Plus exam has been developed.  ViziLite Plus uses technology that has proven successful in identifying soft tissue abnormalities in other areas of the body.  A ViziLite Plus exam is particularly important if you are at increased risk for developing oral cancer.

The ViziLite Plus exam can help your dentist or hygienist identify abnormal tissue, that might develop into oral cancer.

An annual ViziLite Plus exam, in combination with a regular visual examination, provides a comprehensive oral screening procedure for patients at increased risk for oral cancer. The ViziLite Plus exam is painless and fast, and could help save your life.

ViziLite Plus is performed immediately following a regular visual examination

  • First, you will be instructed to rinse with a cleansing solution
  • Next, the overhead lighting will be dimmed.
  • Then, your dental professional will examine your mouth using ViziLite Plus, a specially designed light technology.

    Importance of Early Detection

    Early detection is the key to reducing the devastating impact of oral cancer on victims and their families. Annual oral cancer screening of patients at increased risk for oral cancer, patients age 18 and older, and tobacco users of any age, is the only way to achieve the early detection of oral cancer necessary to reduce the death rate of oral cancer – a death rate that has remained unchanged for more than 40 years!

    The chart below shows how the death rates of other types of cancers have dropped with routine visual/manual screening examinations followed by annual examinations with an adjuctive screening technology. As you can see, when patients at increased risk for breast cancer, prostate cancer and cervical cancer began receiving annual screenings with the mammogram, PSA test and Pap smear, respectively, there was a significant decline in the death rates due to these cancers.

      Screening Technology & Year Introduced Decrease in Death Rates For the Period
    Breast Cancer Mammogram - 1972 45%a 1972-1992
    Prostate Cancer PSA Test - 1986 17.6%b 1993-2002
    Cervical Cancer Pap Smear - 1952 70%-80%c 1950-1990
    Oral Cancer ViziLite Plus - 2002  to be assessed  
  • American Cancer Society
  • Canadian Medical Association CMAJ March 5, 2002:166 (5)
  • American Society of Clinical Pathology, ASCP.org 6-27-03


privacy policy  |  Copyright © 2004-2008 Zila, Inc

Contact Us

We encourage you to contact us with any questions or comments you may have. Please call our office or use the contact form below.
SpamBlocker